Clinical-stage potential Invirsa is a clinical-stage pharmaceutical company focused on a first-in-class approach for diabetic eye diseases, presenting a partnership or licensing opportunity with large- and mid-size pharma players seeking novel mechanisms to address diabetic retinopathy, keratopathy, and related conditions.

Strategic funding Recent Series B financing of 7.7 million signals investor confidence and available runway for BD activities; leverage this momentum to secure co-development, strategic investment, or milestone-based collaborations with pharma companies eyeing expansion into ophthalmology and genomic repair therapies.

Mechanism differentiation INV-102 targets genomic dysfunction from chronic hyperglycemia, restoring CTCF-TAD architecture and upregulating repair pathways, offering a potentially differentiating asset in ophthalmic indications with disease-modifying potential beyond anti-inflammatory or tear-based therapies.

Clinical signals Phase 2 data show statistically significant BCVA improvement in diabetic subjects and signals of innate immune modulation; these signals can be framed for discussions with ophthalmology communicators, payer strategists, and strategic partners to justify further development and market access planning.

Market readiness Headcount is lean (11-50) with a Columbus, Ohio base; opportunities exist to collaborate on regional clinical development, health economics studies, and manufacturing/logistics partnerships to accelerate late-stage trials and potential commercialization in U.S. and global markets.